NCT04401345 is a Phase 4 clinical trial of Glycopyrrolate 0.2 MG/ML in Glycopyrrolate, sponsored by Rajesh Deshar.

Who is sponsoring NCT04401345?

NCT04401345 is sponsored by Rajesh Deshar.

What drugs are being tested in NCT04401345?

Interventions in NCT04401345: Glycopyrrolate 0.2 MG/ML, Normal saline.

What condition does NCT04401345 study?

NCT04401345 studies Glycopyrrolate, Post-spinal Hypotension, Effect of Drug, Hemodynamic Instability.

Is NCT04401345 still recruiting?

NCT04401345 is currently completed. Last updated 21 February 2021.

Last reviewed 2021-02-21 · How we verify

NCT04401345

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Glycopyrrolate on Vasopressors Requirement for Non-elective Caesarean Section Under Spinal Anaesthesia

Completed Phase 4 Last updated 21 February 2021

What this trial tests

Phase 4 trial testing Glycopyrrolate 0.2 MG/ML in Glycopyrrolate in 258 participants. Completed in 31 January 2021.

Timeline

1 June 2020

Primary endpoint
31 January 2021

31 January 2021

Quick facts

Lead sponsor	Rajesh Deshar
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	258
Start date	1 June 2020
Primary completion	31 January 2021
Estimated completion	31 January 2021
Sites	1 location across Nepal

Drugs / interventions tested

Glycopyrrolate 0.2 MG/ML — full drug profile →
Normal saline

Conditions studied

Glycopyrrolate — all drugs for Glycopyrrolate →
Post-spinal Hypotension — all drugs for Post-spinal Hypotension →
Effect of Drug — all drugs for Effect of Drug →
Hemodynamic Instability — all drugs for Hemodynamic Instability →

Sponsor

Rajesh Deshar — full company profile →

Who can join

Adults 18 to 40, female only, with Glycopyrrolate or Post-spinal Hypotension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is prospective randomised double blind study conducted in parturients planned for non-elective caesarean section under spinal anaesthesia. Glycopyrrolate group will receive 0.2 mg of Glycopyrrolate before start of phenylephrine infusion. Control group will receive 0.2 ml of Normal Saline before start of phenylephrine infusion. Total amount of vasopressors required i.e. ephedrine or phenylephrine will recorded in the form of phenylephrine equivalent during intraoperative period.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effect of glycopyrrolate on vasopressor requirements for non-elective cesarean section under spinal anesthesia: a randomized, double-blind, placebo-controlled trial.
Deshar R, Subedi A, Pokharel K, Sah BP, et al · · 2022 · cited 5× · PMID 36284288 · DOI 10.1186/s12871-022-01882-4

Verify or expand the search:

Other recruiting trials for Glycopyrrolate

Currently open trials in the same condition.

NCT06948409 — NMBA Reversal and Postoperative Urinary Retention · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04401345 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rajesh Deshar
Last refreshed: 21 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04401345.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing